Nearly 6.7 million U.S. adults have heart failure.
Lilly shared the topline results in a press release.
The full results from the trial have not yet been published in a journal.
Illustration by Julie Bang for Verywell Health
The company said it will present the full results during an upcoming medical conference.
In the clinical trial, participants taking tirzepatide were 38% less likely to experience a heart failure outcome.
Some other existing medications, likespironolactone, can decrease hospitalizations for people with HFpEF.
However, medications that improve survival rates have been elusive, Khan said.
The fact that this may improve survival, in addition to symptoms, is really exciting.
Lilly also measured how participants heart failure symptoms improved using the Kansas City Cardiomyopathy Questionnaire (KCCQ).
The KCCQ asks questions about those symptoms as well as physical limitations, like difficulty running or showering.
When people who discontinued the treatment are factored in, the average improvement was 6.8 points.
Living longer without feeling better is an insufficient outcome, Khan said.
Being able to say that the symptoms or the how well people feel is just as important.
In April, Lilly shared data showing that tirzepatidereduced sleep apneain people with diabetes.
Novo Nordisk published a study indicating that Wegovy and Ozempic can reduce the risk of kidney disease complications.
Independent research indicates that GLP-1 drugs canreduce the riskof most obesity-associated cancers.
Freeman says he already prescribes GLP-1 medications for his patients with cardiometabolic risk.
Many insurance providers will now cover semaglutide for that use.
Freeman says he is also sometimes able to get coverage for tirzepatide for his patients with heart failure.
Getting insurance coverage could help improve access to the medications, which are prohibitively expensive for many people.
A lot of people would rather just take a pill or an injection than change their lifestyle.
Centers for Disease Control and Prevention.About heart failure.
2022;145(18):e895-e1032.
